Moleculin shareholders approve 5x authorized share increase and reverse split authority

Moleculin Biotech, Inc.

Authorized common shares increased from 100M to 500M (Proposal 8).
Reverse stock split up to 1:20 authorized (Proposal 9); timing not disclosed.
Share issuance for June 23, 2025 warrants (up to 148.7M shares) approved (Proposal 6).
Equity incentive plan shares increased (Proposal 3); say-on-pay approved (Proposal 4).
Supermajority voting amendment failed (Proposal 7); all 6 directors re-elected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.